-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), can cause intestinal damage, and biological agents can be used to treat patients with IBD
Figure: The therapeutic effect of different biological agents on inflammatory bowel disease
This study confirms that CD patients receiving Uselnumumab and UC patients receiving vedolizumab have the highest efficacy and durability
Original source:
Yanna Ko.
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Leave a message here